Terra Firma Capital Corporation Reports First Quarter 2020 Financial Results
All amounts are stated in United States dollars unless otherwise indicated.Q1 2020 Financial Highlights:Revenues increased 3.0% to $4.0 millionAdjusted net […]
SurveyMonkey’s Latest Microsoft Teams App Simplifies Employee Feedback
SAN MATEO, Calif., May 14, 2020 (GLOBE NEWSWIRE) — SurveyMonkey (Nasdaq: SVMK) today announced major new features and updates to […]
Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) — Histogen Inc., a regenerative medicine company with a novel biological platform that […]
Constellation Pharmaceuticals Provides Update of Preliminary Data for CPI-0610 in Three EHA Abstracts
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeksSVR35 responses and transfusion […]
Live Ventures Announces Reopening of Vintage Stock Stores
LAS VEGAS, May 14, 2020 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE), a diversified holding company, today provided a […]
Kratos Mobile Laboratory Product Supporting COVID-19 Response Efforts
SAN DIEGO, May 14, 2020 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), a leading National Security Solutions […]
Cellectar Granted Composition of Matter and Use Patent in Europe for CLR 131
FLORHAM PARK, N.J., May 14, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the […]
mophie debuts new powerstation wireless XL
ORANGE COUNTY, Calif., May 14, 2020 (GLOBE NEWSWIRE) — mophie, a ZAGG Brands (NASDAQ:ZAGG) company and the No. 1 external […]
Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference
NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and […]
Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC
Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response […]
